NEW YORK, NY / ACCESS Newswire / August 26, 2025 / The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired Biohaven Ltd. ("Biohaven" or the "Company") (NYSE:BHVN) securities during the period of from March 24, 2023 through May 14, 2025, inclusive ("the Class Period").
If you suffered a loss on your Biohaven investments, you have until September 12, 2025 to request lead plaintiff appointment. Follow the link below for more information:
[CONTACT THE FIRM IF YOU SUFFERED A LOSS]
What Happened?
On March 3, 2025, Biohaven issued a press release reporting its financial results for the fourth quarter and full year 2024, as well as reporting recent business developments. Among other items, Biohaven reported a loss of $1.71 per share for the quarter, while analysts were expecting a loss of only $1.47 per share. The press release also disclosed that recent data from a late-stage study of the Company’s BHV-7000 drug in bipolar mania "did not statistically separate from the comparator on the Young Mania Rating Scale primary outcome measure". On this news, the price of Biohaven shares declined by $5.12 per share, or approximately 13.77%, from $37.18 per share on February 28, 2025 to close at $32.06 on March 3, 2025.
What Is The Lawsuit About?
The lawsuit alleges that Biohaven made false or misleading statements, or failed to disclose that: (i) it exaggerated the likelihood that troriluzole would receive regulatory approval to treat SCA, as well as the strength of the supporting data; and (ii) it also overstated the effectiveness and clinical potential of BHV-7000 as a treatment for bipolar disorder.
What should I do?
If you purchased or otherwise acquired Biohaven securities, have information, or would like to learn more about this investigation, please contact Thomas W. Elrod of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below, to discuss your rights or interests with respect to these matters at no cost.
[CLICK HERE TO INQUIRE ABOUT THE CLASS ACTION]
Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP’s website.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Contacts
Kirby McInerney LLP
Thomas W. Elrod, Esq.
212-699-1180
https://www.kmllp.com
investigations@kmllp.com
SOURCE: Kirby McInerney LLP
View the original press release on ACCESS Newswire
COMTEX_468322186/2457/2025-08-26T12:46:08